Peptides DB
Research-centric peptide and protocol reference hub
Study 12 of 15Pasireotide literaturebiorxiv-preprint · Observational2025

Hypothalamic deiodinase type-3 establishes the period of circannual interval timing in mammals

Dio3 expression is essential for establishing the period of circannual timing in Djungarian hamsters, but findings may not directly apply to humans.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the pasireotide corpus
1
Preclinical
10
Observational · this one
0
Open-label
0
Randomised
4
Reviews

Summary and findings

This study examined the role of deiodinase type-3 (Dio3) in circannual timing in Djungarian hamsters. The research involved transcriptomic sequencing and targeted mutation of Dio3 using CRISPR-Cas. Results indicated that Dio3 expression is crucial for establishing the period of circannual interval timing.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2025

Abstract

The authors’ words, as biorxiv-preprint supplied them

Animals respond to environmental cues to time phenological events, but the intrinsic mechanism of circannual timing remains elusive. We used transcriptomic sequencing and frequent sampling of multiple hypothalamic nuclei in Djungarian hamster to examine the neural and molecular architecture of circannual interval timing. Our study identified three distinct phases of transcript changes, with deiodinase type-3 ( Dio3 ) expression activated during the early induction phase. Subsequent work demonstrated that targeted mutation of Dio3 using CRISPR-Cas resulted in a shorter period for circannual interval timing. Hamsters that are non-responsive to short photoperiod and fail to show any winter adaptations do not display changes in Dio3 expression do not show any change in body mass or pelage. Our work demonstrates that changes in Dio3 induction is essential for setting the period of circannual interval timing.

Elsewhere in the Pasireotide corpus

BGH responsiveness to corticotropin-releasing hormone identifies corticotroph-like somatotroph adenomas in acromegaly.Pituitary · 2026 · n=65 · Not reported in abstract.HumanBManagement and safety of somatostatin receptor ligands and pegvisomant in pregnant women with acromegaly: a narrative review of the literature.Endocrine · 2026 · n=120 · Symptom worsening occurred in 16.7-40%.reviewBMulti-Layered Molecular Profiling Informs the Diagnosis and Targeted Therapy of Desmoplastic Small Round Cell Tumorbiorxiv-preprint · 2025 · 62% disease control rate among patients receiving recommended therapies.HumanBPrevalence, comorbidities and treatment outcomes of patients with Acromegaly in Qatar. Running title: Acromegaly in Qatarbiorxiv-preprint · 2025 · 1.90 per 100,000 (95% CI: 1.41–2.39)HumanDComparative Efficacy and Safety of Medical Treatments for Cushing’s Disease: A Systematic Review and Network Meta-Analysisbiorxiv-preprint · 2025 · Pasireotide showed a mean difference of -331 (95% CI: -1.75e+03, 1.09e+03) in 24-hour urinary free cortisol reduction.reviewBAdrenocorticotropin-secreting pituitary macroadenomas: expanding the clinical spectrum.JCEM case reports · 2023 · n=3 · Not reported in abstract.Human